Where does Tetraphase Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Tetraphase Pharmaceuticals, Inc. ranks #23,517 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Tetraphase Pharmaceuticals, Inc. hold?

Tetraphase Pharmaceuticals, Inc. holds 12 US utility patents granted between 2016 and 2025, spanning 5 technology areas.

What is Tetraphase Pharmaceuticals, Inc.'s Innovation Score?

Tetraphase Pharmaceuticals, Inc. has an Innovation Score of 26.9 out of 100 (22nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Tetraphase Pharmaceuticals, Inc. focus on?

Tetraphase Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 12 patents, ranking #1,593 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Tetraphase Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Tetraphase Pharmaceuticals, Inc.'s recent grant velocity is -43% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Tetraphase Pharmaceuticals, Inc.'s patents?

Tetraphase Pharmaceuticals, Inc.'s patents average 14.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Tetraphase Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Tetraphase Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 12 granted patents across 5 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Tetraphase ranks #23,517 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 5 technology areas.

#23,517
of 49,997 US assignees by volume: 22nd percentile
by Innovation Score (26.9/100): 14.1
avg claims per patent: -43%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23517 · US Corporation #23,517 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 12 grants
MID-PACK #23,517/49,997
PHOTO-FINISH Taymor Industries
CPC-NARROW A61P · 5 areas
INNOV-THIN 26.9/100
CLAIMS-RICH 14.1 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -43% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Taymor Industries Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Tetraphase’s 26.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.9 pts (33%) Velocity 1.7 pts (6%) Breadth 7.9 pts (29%) Claim depth 8.4 pts (31%)

Qualcomm Incorporated · highest

85
Tetraphase Pharmaceu… · this assignee

27
3D Lighting… · lowest

7

What this shows Tetraphase's Innovation Score is 26.9/100 (22nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Tetraphase?

Each dot is one of Tetraphase’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Tetraphase’s own 14.1 claims/patent is at or below the 16.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Tetraphase vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Tetraphase's grants concentrate

Tetraphase Pharmaceuticals, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2019. By volume, Tetraphase sits between Taymor Industries Ltd. and The Ford Meter Box Company, Inc..

Tetraphase's three-year grant acceleration

Tetraphase Pharmaceuticals, Inc. shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Taymor Industries

12
Techline

12
Techniks

12
Tektronix Texas

12
Texas Fueling Ser…

12
The Board of Trus…

12
The Council of th…

12
The Ford Meter Box

12
Tetraphase Pharma… ◀

12

What this shows Tetraphase holds 12 patents at rank #23,537, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Tetraphase

By rank, the assignees closest to #23,537 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Tetraphase's primary technology class.

Tetraphase's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 22nd percentile higher than 22% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Tetraphase Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	16.7%
2017	2	16.7%
2018	2	16.7%
2019	1	8.3%
2020	1	8.3%
2021	2	16.7%
2023	1	8.3%
2025partial year	1	8.3%

Which technologies does Tetraphase Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

C07D - Heterocyclic Compounds 12

C07C - Acyclic OR Carbocyclic Compounds 8

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

Y02A - Technologies FOR Adaptation TO Climate Change 3

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Tetraphase Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Tetraphase Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #23,517 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Tetraphase Pharmaceuticals, Inc. against Taymor Industries Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.